Suppr超能文献

多药耐药蛋白1核苷酸结合结构域功能特性的比较

Comparison of the functional characteristics of the nucleotide binding domains of multidrug resistance protein 1.

作者信息

Gao M, Cui H R, Loe D W, Grant C E, Almquist K C, Cole S P, Deeley R G

机构信息

Cancer Research Laboratories, Queen's University, Kingston, Ontario K7L 3N6, Canada.

出版信息

J Biol Chem. 2000 Apr 28;275(17):13098-108. doi: 10.1074/jbc.275.17.13098.

Abstract

Multidrug Resistance Protein 1 (MRP1) transports diverse organic anionic conjugates and confers resistance to cytotoxic xenobiotics. The protein contains two nucleotide binding domains (NBDs) with features characteristic of members of the ATP-binding cassette superfamily and exhibits basal ATPase activity that can be stimulated by certain substrates. It is not known whether the two NBDs of MRP1 are functionally equivalent. To investigate this question, we have used a baculovirus dual expression vector encoding both halves of MRP1 to reconstitute an active transporter and have compared the ability of each NBD to be photoaffinity-labeled with 8-azido-[(32)P]ATP and to trap 8-azido-[(32)P]ADP in the presence of orthovanadate. We found that NBD1 was preferentially labeled with 8-azido-[(32)P]ATP, while trapping of 8-azido-[(32)P]ADP occurred predominantly at NBD2. Although trapping at NBD2 was dependent on co-expression of both halves of MRP1, binding of 8-azido-ATP by NBD1 remained detectable when the NH(2)-proximal half of MRP1 was expressed alone and when NBD1 was expressed as a soluble polypeptide. Mutation of the conserved Walker A lysine 684 or creation of an insertion mutation between Walker A and B motifs eliminated binding by NBD1 and all detectable trapping of 8-azido-ADP at NBD2. Both mutations decreased leukotriene C(4) (LTC(4)) transport by approximately 70%. Mutation of the NBD2 Walker A lysine 1333 eliminated trapping of 8-azido-ADP by NBD2 but, in contrast to the mutations in NBD1, essentially eliminated LTC(4) transport activity without affecting labeling of NBD1 with 8-azido-[(32)P]ATP.

摘要

多药耐药蛋白1(MRP1)可转运多种有机阴离子共轭物,并赋予细胞对细胞毒性异生物质的抗性。该蛋白包含两个核苷酸结合结构域(NBDs),具有ATP结合盒超家族成员的特征,并且具有基础ATP酶活性,可被某些底物刺激。目前尚不清楚MRP1的两个NBD在功能上是否等效。为了研究这个问题,我们使用了一种杆状病毒双表达载体,该载体编码MRP1的两个半体以重建一个活性转运体,并比较了每个NBD在正钒酸盐存在下被8-叠氮基-[(32)P]ATP光亲和标记以及捕获8-叠氮基-[(32)P]ADP的能力。我们发现NBD1优先被8-叠氮基-[(32)P]ATP标记,而8-叠氮基-[(32)P]ADP的捕获主要发生在NBD2。尽管在NBD2处的捕获依赖于MRP1两个半体的共表达,但当单独表达MRP1的NH(2)近端半体以及将NBD1表达为可溶性多肽时,NBD1对8-叠氮基-ATP的结合仍可检测到。保守的沃克A赖氨酸684的突变或在沃克A和B基序之间产生插入突变消除了NBD1的结合以及NBD2处所有可检测到的8-叠氮基-ADP捕获。这两种突变均使白三烯C(4)(LTC(4))转运减少了约70%。NBD2沃克A赖氨酸1333的突变消除了NBD2对8-叠氮基-ADP的捕获,但与NBD1中的突变相反,该突变基本上消除了LTC(4)转运活性,而不影响NBD1被8-叠氮基-[(32)P]ATP标记。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验